Vireo Growth (VREOF) Current Deferred Revenue (2020 - 2026)
Vireo Growth (VREOF) posted Current Deferred Revenue of $4.3 million for Q1 2026, down 8.51% sequentially from $4.7 million in Q4 2025, and up 260.28% YoY from $1.2 million in Q1 2025.
Vireo Growth (VREOF) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Vireo Growth has reported Current Deferred Revenue for 7 years, with the latest figure at $4.3 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 260.28% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 260.28% YoY) and the FY2025 annual result came in at $4.7 million, up 346.07% from the prior year.
- Current Deferred Revenue eased to $4.3 million in Q1 2026 per VREOF's latest filing, from $4.7 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $4.7 million in Q4 2025 and troughed at $450334.0 in Q1 2022.
- A 5-year average of $1.4 million and a median of $833832.0 in 2023 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue gained 13.22% in 2023, then jumped 346.07% in 2025.
- Over 5 years, Current Deferred Revenue stood at $684703.0 in 2022, then grew by 21.78% to $833832.0 in 2023, then increased by 26.36% to $1.1 million in 2024, then surged by 346.07% to $4.7 million in 2025, then slipped by 8.51% to $4.3 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $4.3 million, $4.7 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 4.70 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.43 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 921,785.00 |
| Jun 30, 2024 | 821,761.00 |
| Mar 31, 2024 | 885,696.00 |
| Dec 31, 2023 | 833,832.00 |
| Sep 30, 2023 | 732,775.00 |
| Jun 30, 2023 | 626,689.00 |
| Mar 31, 2023 | 710,117.00 |
| Dec 31, 2022 | 684,703.00 |
| Sep 30, 2022 | 647,208.00 |
| Jun 30, 2022 | 522,926.00 |
| Mar 31, 2022 | 450,334.00 |
| Dec 31, 2021 | 409,627.00 |
| Sep 30, 2021 | 424,448.00 |
| Jun 30, 2021 | 374,498.00 |